Vascular Biogenics Alpha and Beta Analysis
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Vascular Biogenics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Vascular Biogenics over a specified time horizon. Remember, high Vascular Biogenics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Vascular Biogenics' market risk premium analysis include:
Beta (0.52) | Alpha 0.63 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Vascular |
Vascular Biogenics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Vascular Biogenics market risk premium is the additional return an investor will receive from holding Vascular Biogenics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vascular Biogenics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Vascular Biogenics' performance over market.| α | 0.63 | β | -0.52 |
Vascular Biogenics Fundamentals Vs Peers
Comparing Vascular Biogenics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vascular Biogenics' direct or indirect competition across all of the common fundamentals between Vascular Biogenics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vascular Biogenics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vascular Biogenics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Vascular Biogenics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Vascular Biogenics to competition |
| Fundamentals | Vascular Biogenics | Peer Average |
| Return On Equity | -0.6 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Operating Margin | (33.89) % | (5.51) % |
| Current Valuation | (10.99 M) | 16.62 B |
| Shares Outstanding | 77.64 M | 571.82 M |
| Shares Owned By Insiders | 13.48 % | 10.09 % |
| Shares Owned By Institutions | 14.00 % | 39.21 % |
Vascular Biogenics Opportunities
Vascular Biogenics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update | 05/15/2023 |
2 | Contrasting Vascular Biogenics and Sigilon Therapeutics | 05/17/2023 |
3 | Vascular Biogenics Research Coverage Started at StockNews.com | 07/03/2023 |
About Vascular Biogenics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Vascular or other delisted stocks. Alpha measures the amount that position in Vascular Biogenics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Vascular Biogenics Upcoming Company Events
As portrayed in its financial statements, the presentation of Vascular Biogenics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vascular Biogenics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Vascular Biogenics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Vascular Biogenics. Please utilize our Beneish M Score to check the likelihood of Vascular Biogenics' management manipulating its earnings.
| 13th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Build Portfolio with Vascular Biogenics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |